DANNCE.AI is bringing to market DANNCE, a novel phenotyping platform to digitize the clinical assessments used by doctors and therapeutic developers to quantify movement. DANNCE is a new approach to the clinical exam that ingests videos of patients and automatically analyzes them for evidence of neurological disease. The platform can also evaluate the efficacy of drugs for patients with neurological disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/29/24 | $2,600,000 | Pre-Seed |
Duke Capital Partners Glasswing Ventures LDV Capital  Leo Lion Merck Digital Sciences Studio | undisclosed |
